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(57) 	 ABSTRACT 
Three-dimensional human broncho-epithelial tissue-like 
assemblies (TLAs) are produced in a rotating wall vessel 
(RWV) with microcarriers by coculturing mesenchymal 
bronchial-tracheal cells (BTC) andbronchial epithelium cells 
(BEC). These TLAs display structural characteristics and 
express markers of in vivo respiratory epithelia. TLAs are 
useful for screening compounds active in lung tissues such as 
antiviral compounds, cystic fibrosis treatments, allergens, 
and cytotoxic compounds. 
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ENGINEERED HUMAN 
BRONCHO-EPITHELIAL TISSUE-LIKE 
ASSEMBLIES 
FEDERALLY SPONSORED RESEARCH 
STATEMENT 
This work has been supported by NASA's Biological Sci-
ences and Applications Division. The invention described 
herein is subject to the provisions of Section 305 of the 
National Aeronautics and Space Act of 1958, Public Law 
85-568 (72 Stat. 435; 42 U.S.C. 2457). 
PRIOR RELATED APPLICATIONS 
Not applicable. 
REFERENCE TO MICROFICHE APPENDIX 
Not applicable. 
FIELD OF THE INVENTION 
In vitro three-dimensional (3D) human broncho-epithelial 
(HBE) tissue-like assemblies (31) HBE TLAs) from this point 
forward referred to as TLAs were engineered in Rotating Wall 
Vessel (RWV) technology to mimic the characteristics of in 
vivo tissues. 
BACKGROUND OF THE INVENTION 
Respiratory epithelium is critical in protecting humans 
from disease and acts as a barrier to invading microbes 
present in the air. Airway epithelial cells defend the host 
physiology by blocking paracellular permeability, modulat-
ing airway function through cellular interactions, and trans-
porting inhaled microorganisms away via ciliated epithelial 
cells (Bals and Hiemstra, 2004, Cotran et al, 1999). Epithelial 
cells are regulators of the innate immune response and also 
induce potent immunomodulatory and inflammatory media-
tors (cytokines and chemokines), thus recruiting phagocytic 
and inflammatory cells and facilitating microbial destruction 
(Bals and Hiemstra, 2004; Knight and Holgate, 2003). 
The respiratory epithelia defend the host through a com-
plex multi-layered system of pseudo-stratified epithelial 
cells, a basement membrane, and underlying mesenchymal 
cells (Hiemstra and Bals, 2004). Ciliated, secretory, and basal 
epithelial cells are joined by intercellular junctions and 
anchored to the basement membrane via desmosomal inter-
actions. Through tight junctions and the mucociliary layer, 
the basement membrane maintains polarity of the epithelium 
and presents a physical barrier between the mesenchymal 
layer and the airway (Knight and Holgate, 2003; Gibson and 
Perrimon, 2003). Spatial cellular relationships, cell mem-
brane junctions, extracellular matrices (e.g., basement mem-
brane and ground substances), and soluble signals (endo-
crine, autocrine, and paracrine) influence tissue 
differentiation. Complex recapitulated 3D models must emu-
late these complex cellular relationships to model character-
istics of in situ airway epithelium. 
Current models of in vivo lung epithelium are limited by 
fidelity of the model and scale. Traditional two-dimensional 
(2D) monolayer cultures such as immortalized human epithe-
lial cell lines and primary normal human bronchial epithelial 
(NHBE) cells as well as air-liquid interface cultures (3D) fail 
to express the innate tissue fidelity characteristic of normal 
human respiratory epithelia (Carterson et al., 2005). Thus, 
2 
their state of differentiation and intracellular signaling path-
ways differ from epithelial cells in vivo. Recently, 3D aggre-
gates derived from an alveolar epithelial tumor cell line 
(A549) were used as targets for bacterial infection (Carterson 
5 et al., 2005). While superior to two dimensional cultures, the 
3D aggregates lacked the functional and structural character-
istics of airway epithelium in situ. Primary isolates of HBE 
cells provide a pseudo-differentiated model with structure 
and function similar to epithelial cells in vivo; however, this 
to fidelity is short-lived in vitro (Gray et al, 1996). Air-liquid 
interface cultures of primary HBE cells (or submerged cul-
tures of human adenoid epithelial cells Wright et al, 2005) are 
grown on collagen-coated filters in wells, on top of a perme-
able filter. These cells receive nutrients basolaterally and their 
15 apical side is exposed to humidified air. The result is a culture 
of well-differentiated heterogeneous (ciliated, secretory, 
basal) epithelial cells essentially identical to airway epithe-
lium in situ (Adler and Li, 2001). Although this model mimics 
the fidelity of the human respiratory epithelium in structure 
20 and function, maintenance of consistent cultures is difficult, 
time consuming, and restricted to small-scale production. 
Culturing normal 3D epithelium configurations larger than 
3 mm is problematic using traditional in vitro culture tech-
nology. Short-term cultures have been accomplished but, 
25 long-term growth requires sophisticated, defined culture 
media or in vitro transformation to increase longevity. To 
address this, horizontally rotating cylindrical tissue culture 
vessels or rotating wall vessels (RWV) developed at NASA's 
Johnson Space Center (Schwarz et al, U.S. Pat. No. 5,026, 
3o 650) have been used to model many 3D tissues (Goodwin et 
al, 1988, 1992, and 1993) (Table 1). This technology allows 
the recapitulated tissues to be used as host targets for viral 
infectivity (Goodwin et al., 2000) by providing controlled 
supplies of oxygen and nutrients, with minimal turbulence 
35 and extremely low shear (Schwarz et al, 1992). These vessels 
rotate the wall and culture media inside at identical angular 
velocity, thus continuously randomizing the gravity vector 
and holding particles such as microcarriers and cells rela-
tively motionless in a quiescent fluid (Schwarz et al 1992; 
4o Tsao et al, 1992). 
TABLE 1 
3D TISSUES ENGINEERED IN THE ROTATING WALL VESSEL 
45 NORMAL Ref 
Bovine Cartilage (chondrocytes) (Baker, 1997) 
Rat Cardiomyocytes (Bursae, 2003) 
Human Bone (Osteoblast) (Klement, 2004; Wang, 2005) 
Human Cornea (O'Connor, 1999) 
50 Human Kidney (Goodwin, 1993; Hammond, 1997) 
Human Liver (Yoffie, 1999) 
Human Lymphoid (Margolis, 1997; Pellis, 1997) 
Human Neural Progenitor (Goodwin, 2003; Goodwin, 2005) 
Human Renal Proximal Tubule (Hammond, 1997) 
Human Small Intestinal Epithelial (Goodwin, 1993) 
55 
CANCER 
Human Colon (Goodwin, 1988; Goodwin, 1992) 
Human Lung (Vertrees, 2005) 
Human Ovarian (Goodwin, 1997) 
60 Human Prostate (Wang, 2005) 
Optimally, a cell-based respiratory epithelia model would 
reproduce the structural organization, multicellular complex- 
ity, differentiation state, and function of the human respira- 
65 tort' epithelium. Here we report the successful engineering of 
the first in vitro model of the human respiratory epithelium 
using primary mesenchymal hBTCs as the foundation matrix 
US 8,338,114 B1 
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and an adult HBE immortalized cell line BEAS-213 as the 
overlying component. The RWV culture system provides 
ease of manipulation, consistency in culture conditions, and 
well-differentiated TLAs that share structural and functional 
characteristics of the human respiratory epithelium. When 
combined with a solid matrix, cocultivation of epithelial and 
mesenchymal cells in RWVs allow cells to auto assemble into 
3D tissue-like masses that we postulate fulfill four of the five 
basic stages of tissue regeneration and differentiation (FIG. 
2). Like the air-liquid interface model (O'Brien et al, 2002), 
the epithelial cell organization of the TLAs improves the 
expression of airway epithelial characteristics, and also cel-
lular communication. Thus, TLAs represent a physiologi-
cally relevant model of the human respiratory epithelia that 
can be used in large-scale production for prolonged periods. 
TABLE 2 
ABBREVIATIONS 
Abbr 	 Term 
2D Two-Dimensional 
3D Three-Dimensional 
ATCC ® American Tissue-type Culture Collection 
BE Broncho-Epithelial 
BME Eagle's Basal Medium 
BSA Bovine Serum Albumin 
BTC Broncho-Tracheal Cells 
BV Budding Virus 
CF Cystic Fibrosis 
CMF-PBS calcium- and magnesium-free PBS 
DEAE Diethylamino Ethanol 
DMEM Dulbecco's MEM 
DPBS Dulbecco's PBS 
ECM Extracellular Matrix 
EMA Epithelial Membrane Antigen 
EMEM Eagle's MEM 
FBS Fetal Bovine Serum 
FVIII Factor VIII 
GTSF Glucose Trisugar Formula 
H&E Haematoxylin and Eosin 
hBE Human Broncho-eptihelial 
hBTC Human Mesenchymal BTC 
HIV Human Immunodeficiency Virus 
ICAM Intercellular Adhesion Molecule 
IHC Immunocytochemistry 
IMDM Iscove's Modified Dulbecco's Medium 
MEM Minimal Essential Medium 
MOI Multiplicity of Infection 
MV Microvilli 
NHBE Primary Normal hBE 
PBS Phosphate-Buffered Saline 
PECAM Platelet/Endothelial Cell Adhesion Molecule 
pfu Particle Forming Units 
pi Post Infection 
PIV Paminfluenza Virus 
RARP Retinoic Acid Receptor beta 
RSV Respiratory Syncytial Virus 
RWV Rotating Wall Vessel 
SEM Scanning Electron Micrograph 
SPA Surfactant Protein A 
SPG Sucrose-Phosphate-Glyoxylic acid 
TEM Transmission Electron Micrograph 
TJ Tight Junction 
TLA Tissue-Like Assemblies (3D-HBE) 
V Vacuole 
VNC Virus Nucleocapsid 
wt Wild-Type 
ZO Zonula Occludens 
SUMMARY OF THE INVENTION 
The construction of a functionally accurate, large-scale, 
3D in vitro tissue model of the human airway is a major 
advance for lung research. The recapitulation of large TLAs 
4 
that express differentiated epithelial and mesenchymal cell 
markers offers a multitude of possibilities for cell biological 
investigations. Functional epithelial cell brush borders with 
extracellular matrix and basal lamina components represent 
5 ordering of tissue and cellular polarity nurtured by the 
molecular conditions and physical orientations of the culture 
system. These data are confirmed in FIG. 4 (NC) and FIG. 5 
(TEMs) and represent concomitant cellular differentiation 
marker expression and architectural ordering when compared 
10 to normal human tissue. Additionally, this 3D model demon-
strates a significantly diminished requirement for complex 
culture media in the RWV culture system. The growth of 
mesenchymal and epithelial cells in the absence of complex 
media infers specific cell-cell interactions and the production 
15 of the paracrine and autocrine factors essential to the growth, 
development and differentiation of these fragile tissues. 
This model of human TLAs embodies many aspects of 
differentiation observed in other in vitro and in vivo cell and 
organ models. Primary distinctions for this model are: (i) the 
20 overall scale of the model, (ii) the ability to culture epithelium 
for periods in excess of 40 days without loss of functional cell 
markers, (iii) the ability to maintain viral production and 
cellular repair while maintaining the model, and (iv) the abil-
ity of the system to respond to extensive analyses and manipu- 
25 lations without the termination of a given experiment. Future 
experiments will use genomic andproteomics technologies to 
clarify and characterize the potential of this new model sys-
tem. Of particular interest will be regulation of unique cytosk-
eletal proteins such as villin, functional markers such as tubu- 
30 lin, ZO-1, EMA, ICAM-1, a myriad of inflammatory 
response modifiers, and other markers that may be repre-
sented more accurately by large-scale 3D modeling. 
The molecular basis of inflammatory responses and patho-
genesis of the human lung to many airborne and blood borne 
35 infections may be investigated with the advent of this new 
technology. Further, clinical response and treatment of dis-
eases may be accomplished more efficiently as a result of 
rapid vaccine development (Deatly et al, submitted). Analo-
gous to the data presented for RSV and PIV, the human 
40 immunodeficiency virus (HIV) can replicate in human 3D 
lymphoid tissues and complex epithelium maintained in the 
RWV, thus immunodeficiency virus-host interactions in the 
RWV culture system may be possible (Moyer et al, 1990, 
1990b, Margolis 1997). Therefore broad application of this 
45 culture model may lead to advances in understanding the 
developing human lung, the potential treatment of a myriad of 
clinical conditions, and advances in regenerative medicine. 
BRIEF DESCRIPTION OF THE FIGURES 
50 
The patent or application file contains at least one drawing 
executed in color. Copies of this patent or patent application 
publication with color drawing(s) will be provided by the 
Office upon request and payment of the necessary fee. 
55 	 FIG. 1: Tissue assembly process in a Rotating Wall Vessel. 
FIG. 2: Five stages of tissue development and assembly. 
FIG. 3: Glucose utilization. Glucose utilization and pH 
curves for a healthy 3D culture. Standard error of the Mean 
for the pH data is <0.08. 
60 FIG. 4: Comparative IHC staining. Comparative IHC 
staining of normal human lung tissue samples (FIG. 4A, FIG. 
4C, FIG. 4E, FIG. 4G, FIG. 4I, FIG. 4K, FIG. 4M, FIG. 40, 
FIG. 4Q, FIG. 4S, FIG. 4U. FIG. 4W, and FIG. 4Y) and 
recapitulated TLAs (FIG. 413, FIG. 4D, FIG. 4F, FIG. 4H, 
65 FIG. 4J, FIG. 4L, FIG. 4N, FIG. 4P, FIG. 4R, FIG. 4T, FIG. 
4V, FIG. 4X, and FIG. 4Z) formed in the RWV. Photos are 
arrayed in matched pairs showing the normal human tissue 
US 8,338,114 B1 
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and the TLAs were stained for PECAM-1 (FIG. 4A and FIG. 	 TLAs are produced in cell cocultures with mesenchymal 
413), EMA (FIG. 4C and FIG. 4D), tubulin (FIG. 4E and FIG. 	 bronchial-tracheal cells (BTC) andbronchial epithelium cells 
4F), cytokeratin 8 (FIG. 4G and FIG. 4H), Factor VIII (FIG. 	 (BEC). These TLAs express markers of in vivo respiratory 
4I and FIG. 47), mucin (FIG. 4K and FIG. 4L), villin (FIG. 	 epithelia and display structural characteristics of in vivo res- 
4M and FIG. 4N), cytokeratin 18 (FIG. 40 and FIG. 4P), 5 piratory epithelia. In one embodiment of the invention pri- 
ZO-1 (FIG. 4Q and FIG. 4R), ICAM-1 (FIG. 4S and FIG. 4T), 	 mary human mesenchymal bronchial-tracheal cells (hBTC) 
and collagen IV (FIG. 4Y and FIG. 4Z). Sample pairs FIG. 4U 	 and human bronchial epithelial immortalized cells (BEAS- 
and FIG. 4V and FIG. 4W and FIG. 4X are H&E histologies 	 132) are cocultured. 
demonstrating human tissue organization and TLA cell den- 	 TLAs can be produced in a RWV with culture media and 
sity. All samples are shown at 400x magnification. 	 io microcarriers by inoculating with BTC cells, growing BTC 
FIG. 5: TEMs of uninfected TLAs. FIG. 5A and FIG. 5B 	 cells for 24 to 240 hours, and subsequently inoculating with 
(mag. x7,500) show TLAs that are multilayered (6 or 7 layers 	 BEC cells. The coculture can be grown for 24 to 960 hours to 
of long thin cells with dark nuclei) and demonstrate extracel- 	 produce TLAs. These TLAs express markers of in vivo res- 
lular matrix material between the cells; FIG. 5C and FIG. 5D 	 piratory epithelia and display structural characteristics of in 
(mag. x7,500) demonstrate both mesenchymal and epithelial 15 vivo respiratory epithelia. 
cells (oval and elongated nuclei) lying close to the bead sur- 	 The microcarriers and culture media can be selected to 
face; FIG. 5E and FIG. 5F (mag x50,000) demonstrate cellu- 	 have less than a 10% difference in density, more preferably 
lar tight junctions (TJ) and microvilli (MV) are visible in FIG. 	 less than a 5% difference in density, and most preferably less 
5F. 	 than a 2% difference in density. The difference in density can 
FIG. 6: SEMs of TLAs infected with wtRSVA2. FIG. 6A 20 be calculated as 100 times the fraction of microcarrier density 
and FIG. 6B demonstrate healthy non-infected (smooth) epi- 	 over media density or media density over microcarrier den- 
thelium; FIG. 6C and FIG. 6D demonstrate clusters of bud- 	 sity. Acceptable differences in density range continuously 
ding virus (BV) atop the epithelium on day 2 and 4 post 	 from 90%-110% including all intermediate values. 
infection (pi); FIG. 6E illustrates the result of viral infection 	 Compounds can be assayed using TLAs to determine anti- 
of the epithelial layer on day 8 pi. Notice the pock-marked 25 viral activity, identify putative CF treatments, quantitate aller- 
appearance of the once smooth epithelium. FIG. 6F demon- 	 gen activity, or determine compound cytotoxicity. One assay 
strates an inset of budding virus masses from an infected 	 may be performed by dividing TLA producing cocultures into 
epithelium on day 12 pi. 	 two or more separate cocultures. One set of experimental 
FIG. 7: TEMs of wtRSVA2 infected TLA epithelium. FIG. 	 TLAs can be exposed to a test compound, while a second set 
7A is an uninfected micrograph showing a tight junction (T7) 30 of control TLAs are not. Additional control TLAs may be 
between cells at time zero. FIG. 7B demonstrates viral 	 exposed to compounds with a known activity. TLAs can be 
nucleocapsids (VNC) present in the perinuclear area of the 	 assayed in the presence or absence of viral infection, with cell 
cell at 1 hr pi. Both FIG. 7A and FIG. 7B shown at mag. 	 lines from cystic fibrosis sufferers, as well as other lung 
x50,000. FIG. 7C (mag. x50,000) and FIG. 7D (mag. x12, 	 diseases. 
000) illustrate the presence of budding virus (BV) at 2 and 4 35 	 Mesenchymal bronchial-tracheal cells (hBTC) include pri- 
days pi, respectively, and vacuoles (Vs) in FIG. 7D at day 4 pi. 	 mary cultures of mesenchymal bronchial-tracheal cells, as 
FIG. 7E (mag. x50,000) and FIG. 7F (mag. x25,000) show 	 well as fibroblasts and myofibroblasts. Bronchial cell strains 
VNC present in the cells at days 8 and 12 pi, respectively. 	 include HFLL HS-1Lu, CCD-8Lu, CCD-13Lu, CCD-25Lu; 
FIG. 8: Expression of RSV. Increase in expression of RSV 
	 human embryonic pulmonary fibroblast (W138); and fetal 
FIG. 8F and FIG. 8G glycoproteins from day 2 to 10 pi. 	 40 lung fibroblasts (IMR-90, MRC-5, HFLF). Cell lines may be 
FIG. 9: Growth kinetics. Growth kinetics of wtRSVA2 and 
	 from a variety of sources including mammals, primates 
wtPIV3 7S in recapitulated TLAs up to day 21. 	 (DBS-FCL-1), dog, cat (FC2.Lu), mouse, and rat (RLF). Cell 
lines may or may not be transformed with a virus prior to or 
DETAILED DESCRIPTION OF THE INVENTION 	 after inoculation. Some cell lines that contain virus include 
45 WI-38-VA13, WI-26-VA4, XP12RO, HFL-1, and M3E3/C3. 
In vitro TLAs were engineered in RWV to mimic the 	 Bronchial epithelial cell lines include primary cultures of 
characteristics of in vivo tissues thus providing a tool to study 	 bronchial epithelial cells (BEC), normal bronchial epithelium 
human respiratory viruses and host cell interactions. The 	 (e.g. 16-HBE, HBE135, NHBE, HTBE); immortalized bron- 
TLAs were bioengineered onto collagen-coated cyclodextran 	 chial epithelium (BEAS-213, BEAS-S6, BEAS39, BEP21), 
microcarriers using primary human mesenchymal bronchial- 5o BES-IAL BET-IA, BZR, HEp-2, NL20, SK-LU 1); fetal 
tracheal cells (HBTC) as the foundation matrix and an adult 	 broncho epithelium (9HTEo-); fetal lung epithelium (MRC- 
human bronchial epithelial immortalized cell line (BEAS- 	 5); alveolar epithelium (R3/1, L2); trachea epithelium (CF- 
213) as the overlying component. The resulting TLAs share 	 PEo); and Cystic Fibrosis (CF) epithelium (CFSMEo, 
significant characteristics with in vivo human respiratory epi- 	 CFBE410-, I133-1). Cell lines maybe from a variety of sources 
thelium including polarization, tight junctions, desmosomes, 55 including mammals, primates (4 MBr-5, 12 MBr6), dog, cat 
and microvilli. The presence of tissue-like differentiation 	 (AK-D), mouse (MM14.Lu), and rat (EIA-T2). Cell lines 
markers including villin, keratins, and specific lung epithe- 	 may or may not be transformed with a virus prior to or after 
lium markers, as well as the production of tissue mucin, 	 inoculation. Some cell lines that contain viruses include 
further confirm these TLAs differentiated into tissues func- 	 HBE135-E6E7, HBE4-E6/E7, HBE4-E6/E7-Cl, and BBM. 
tionally similar to in vivo tissues. Increasing virus titers for 60 	 Other lung and bronchial cell lines (e.g. FHs-738Lu, HE- 
human respiratory syncytial virus (wtRSVA2) and parainflu- 	 LU(Rifkin), Hs-412.Lu, Hs-115.Lu) and numerous carcino- 
enza virus type 3 (wtPIV3 7S) and the detection of membrane 	 genic cell lines (e.g. A549, NCI-H441, 16HBE4o-, NCI- 
bound glycoproteins over time confirm productive infections 	 H292) are also available for cell culture using the RWV. 
with both viruses. Therefore, TLAs mimic aspects of the 	 Although these cell lines are in various stages of character- 
human respiratory epithelium and provide a unique capability 65 ization, they may prove useful as either mesenchymal or 
to study the interactions of respiratory viruses and their pri- 	 epithelial cell lines depending upon their ability to differen- 
mary target tissue independent of the host's immune system. 	 tiate in the RWV under various growth conditions. AwRicAN 
US 8,338,114 B1 
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TYPE CULTURE COLLECTIONTM (ATCC(t) (Manassas, Va.), has 
many publicly available cell strains, incorporated herein by 
reference. 
Respiratory Syncytial Virus (RSV) is available from a vari-
ety of sources. Examples include human respiratory syncytial 
virus A-2 (ATCC VR-1540TM), human respiratory syncytial 
virus B (ATCC VR-1400TM), human respiratory syncytial 
virus 9320 (ATCC VR-955TM), human respiratory syncytial 
virus Wash/18537/'62 (ATCC VR-1580TM), human respira-
tory syncytial virus Long (VR-26), among others. 
Parainfluenza virus (KV) includes parainfluenza virus 1 
(ATCC VR-94TM), parainfluenza 2 (ATCC VR-92TM), parain-
fluenza Greer (ATCC VR-1381TM), Parainfluenza 4a (ATCC 
VR-1378TM), parainfluenza 4b (ATCC VR-1377TM), and 
parainfluenza 5 DA (ATCC VR-263TM) 
Other viruses that infect the naso-pharynx, trachea, and 
lungs include human rhinoviruses (HRV), coxsackieviruses, 
echoviruses, severe acute respiratory syndrome virus 
(SARS), adenovirus, influenza A and B, Hantavirus, and 
cytomegalovirus (CMV). Some viruses have multiple symp-
toms that could include lung infection. Some common viruses 
associated with multisystem syndromes include paramyxovi-
rus species (measles), varicella-zoster virus, Epstein-Barr 
virus, CMV, herpes simplex virus, and human immunodefi-
ciency virus (HIV). 
GTSF-2 is a unique trisugar-based medium, containing 
glucose, galactose, and fructose formulated at NASA's 
Johnson Space Center (U.S. Pat. No. 5,846,807). GTSF-2 
media can be used with or without supplemental ingredients 
including 10% fetal bovine serum (FBS). Although GTSF-2 
is optimized for RWV cultures, other culture media may be 
substituted and function in a similar manner. Culture media 
include commercial media supplied by ATCC® (Manassas, 
Va.), SIGMA-ALDRICH® (St. Louis, Mo., U.S.A.), GiaCo® (IN-
VITROGEN®, Carlsbad, Calif.), EUROCLONEO (Milano, Italy) 
and others. Common tissue culture media include Eagle's 
Basal Medium (BME), Dulbecco's Modified Eagle's 
Medium (DMEM), DMEM: F12 Medium, Eagle's Minimum 
Essential Medium (EMEM), F-12K Medium, Iscove's Modi-
fied Dulbecco's Medium (IMDM), Leibovitz's L-15 
Medium, McCoy's 5A Medium Modified, RPMI 1640 
Medium, or customized culture media with various salts, 
amino acids, peptides, and supplements that facilitate cell 
growth. 
Microcarriers are available in a variety of materials includ-
ing Cylindrical DEAE cellulose anion exchangers (e.g. 
DE-52, DE-53), DEAE-SEPNADExTM A-50, polystyrene, 
derivatized polyacrylamide, cross-linked dextran, DEAE-
dextran, silicone, gelatin, glass, or other suitable material. 
Changes in porosity and charge can affect cell growth on 
various microcarriers. Microcarriers can be coated with vari-
ous surface compounds to improve cell growth including 
collagen, pronectin, modified collagen, denatured collagen, 
DEAF, peptides, and charged compounds. One example is 
collagen-coated cyclodextran microcarriers where the dext-
ran beads are coated with cross-linked denatured collagen 
and provide a natural surface for cell growth. Microcarriers 
are available from various sources examples include glass-
coated microcarriers (BIOSIL®, Paterson, N.J.), VENTREGELO 
collagen microcarriers (VENTREx(t LAB., Portland, Me.), 
CuLTiSPEERTM G gelatin microcarriers (SIGMA®, St. Louis, 
MO.), GELIBEADTM cross-linked gelatin microcarriers (KC-
BiOLOGiCALSTM, Lenexa, Kans.), collagen-coated polystyrene 
(KONTEs LIFE SCIENCES PRODUCTS®, Vineland, N.J.), CYTOOEx-
1TM DEAE-dextran microcarriers (PEIARMACIAO Piscataway, 
N.J.) and CYTODEx-3TM collagen-linked DEAE-dextran 
microcarriers (PHARMAcEAM Piscataway, N.J.). 
8 
Rotating Wall Vessel (RWV) is a horizontally rotated cul-
ture vessel with zero headspace and center oxygenation. The 
RWV is a suspension culture vessel optimized to produce 
laminar flow and minimize the mechanical stresses on cell 
5 aggregates in culture. In an embodiment, the RWV provides 
an environment for enhancing the culture of cells and living 
3-dimensional tissues by controlling the fluid mechanical 
environment to achieve the predetermined culture character-
istics. More specifically, use of the RWV effectuates the 
10 
capability to simultaneously achieve a culture environment 
with reduced fluid shear stress, freedom for 3-dimensional 
spatial orientation (of suspended particles), and localization 
of particles with differing (or similar) sedimentation proper-
ties in a similar spatial region (collocation). The minimal fluid 
shear stress obtainable in unit gravity (i.e., 9.8 m/sec 2) is 
15 determined by the gravitationally induced motion of the sus-
pended particles of the horizontally rotating culture vessel 
through the culture medium. Further, the RWV provides a 
means for a supply of nutrients and removal of metabolic 
waste products. This is accomplished either by perfusion of 
20 media through an external media perfusion loop, direct injec-
tion to the culture media, or exchange of these molecules 
across a diffusion membrane. Additional details are found in 
U.S. Pat. No. 5,155,034 to Wolf et al., which is incorporated 
by reference in its entirety. Terminal velocity in a RWV 
25 culture is minimized by choosing microcarrier beads and 
culture media as close in density as possible. Preferably the 
microcarrier beads and culture media will have less than a 
10%, 9%,8%,7%,6%,5%,4%,3%,2%, or 1% difference in 
density. Most preferably the microcarrier beads and culture 
30 media would have equivalent densities with less than 1% 
difference in density. 
TLAs are engineered cells comprising epithelial and mes-
enchymal cell types. TLAs share significant characteristics 
with in vivo human respiratory epithelium including polar- 
35 ization, tight junctions, desmosomes, microvilli, and tissue-
like differentiation markers. 
Tissue-like differentiation markers include: basement 
membrane and extracellular matrix components (e.g., col-
lagen IV); epithelial and mesenchymal cell markers; specific 
40 lung epithelium markers; cell adhesion molecules; extracel-
lular matrix (ECM) markers; surfactant proteins; secretory 
proteins; inflammatory response modifiers; tight junctions 
(including ZO-1); polarization (e.g. EMA); claudins; col-
lagens; collagen IV; cytokeratins; cytokeratin 8; cytokeratin 
45 18; epithelial membrane antigen (EMA); epithelial cell sur-
face marker (EPM-1), Factor VIII; intercellular adhesion 
molecule (ICAM-1); keratins; laminin, lectin; lysozyme, 
mucin; platelet/endothelial cell adhesion molecule (PECAM-
1); retinoic acid receptor beta (RARP); surfactant protein A 
50 (SPA); tubulin; villin; vimentin; and zonula occludens-1 (ZO-
1), among other differentiation specific markers. 
Phenotypic or qualitative traits include cell shape, cell 
types, cell anomalies, TLA structure, and other morphologi-
cal characteristics. Examples include traits such as the pres- 
55 ence and/or position of cell differentiation markers in the 
TLA. 
Quantitative traits include cell size measurements, fluores-
cence, IHC measurement, and other analytical measure-
ments. Examples include the measurement of cell differen- 
60 tiation markers in the TLA. 
Example 1 
Materials & Methods 
65 
Viruses and strains used in certain embodiments of the 
invention are set forth in Table 3. 
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TABLE 3 
VIRUSES & STRAINS 
Virus Genotype Ref 
wtRSVA2 wild-type human respiratory ATCC VR-1540 TM 
syncytial virus 
wtPIV3 JS wild-type parainfluenza ATCC VR-94 TM 
virus type 3 
Strain Description Ref 
hBTC primary human mesenchymal CAMBREX 
bronchial-tracheal cells 
BEAS-213 human bronchial epithelial ATCC CRL-9609 TM 
immortalized cell line 
HEp-2 HeLa contaminant ATCC CCL-23 TM 
LLC-MK2 Kidney ATCC CCL-7 TM 
Cell Cultures and Media 
Mesenchymal cells (hBTC) from human bronchi and tra-
cheae were obtained from the lung mucosa of multiple tissue 
donors through CAMBREX BIOSCIENCES® (Walkersville, Md.). 
BEAS-213 epithelial cells were obtained from ATCC® (Ma-
nassas, Va.). All were harvested and banked at the NASA 
Johnson Space Center's Laboratory for Disease Modeling 
and shown to be free of viral contamination by survey of a 
panel of standard adventitious viruses (e.g. HIV, hepatitis, 
herpes) conducted by the manufacturer. Cells were initiated 
as monolayers in human fibronectin coated flasks (BD Bio-
SCIENCES®, San Jose, Calif.) and propagated in GTSF-2 media 
supplemented with 10% FBS. All cell cultures were grown in 
a FORMA® (Marietta, Ohio) humidified CO z incubator with 
95% air and 5% COz, and constant atmosphere at a tempera-
ture of 37° C. Normal hBTC mesenchymal and BEAS-213 
human lung cells were passaged as required by enzymatic 
dissociation with a solution of 0.1% trypsin and 0.1 % EDTA 
for 15 minutes at 37° C. After incubation with the appropriate 
enzymes, the cells were centrifuged at 800 g for 10 minutes in 
Corning conical 50 ml centrifuge tubes. The cells were then 
suspended in fresh medium and diluted into T-flasks with 30 
ml of fresh growth medium. BEAS-213 epithelial cells were 
passaged as required by dilution at a 1:4 ratio with GTSF-2 
media in T-flasks. 
RWV Cultures 
Normal mesenchymal cell monolayers were removed from 
T-75 flasks by enzymatic digestion, washed once with CMF-
PBS, and assayed for viability by trypan blue dye exclusion 
(INVITROGEN®, Carlsbad, Calif.). Cells were held on ice in 
fresh growth medium until inoculation. The primary inocu-
lum for each coculture experiment was 2x10 5 hBTC mesen-
chymal cells/ml in a 55-m1 RWV with 5 mg/ml of CYTODEx-
3TM microcarriers 120 M in diameter. Cultures were allowed 
to grow for a minimum of 24 to 48 hours before the medium 
was changed. Thereafter, fresh medium was replenished by 
65% of the total vessel volume each 20 to 24 hours. BEAS-213 
epithelial cells were added at 2x10 5 cells/ml on day 4. As 
metabolic requirements increased, fresh medium was supple-
mented with an additional 100 mg/dl of glucose. Coculture 
experiments in the RWV were grown in GTSF-2 supple-
mented with 10% fetal bovine serum (Goodwin et al 1992, 
1993). The optimal period of culture was 15-20 days prior to 
infection with virus. Experiments were cultured for up to 40 
days total including post infection (pi). Viable cocultures 
grown in the RWV were harvested over periods up to 21 days 
and prepared for various viral infectivity assays. All RWV 
cell cultures were grown in a FORMA® (Marietta, Ohio) 
humidified CO2 incubator with 94.5% air and 5.5% CO 2 
10 
providing constant atmosphere and a temperature of 35.5° C. 
to mimic that of the nasopharyngeal epithelium (McFadden, 
1985). 
3D Cell Growth Kinetics 
5 	 The cocultures were sampled over the course of the experi- 
ments, generally at 48-hour time points, in order to establish 
a cellular development profile. The parameters of glucose 
utilization and pH were surveyed via I-STATO (Princeton, 
N.J.) clinical blood gas analyzer to determine the relative 
10 progress and health of the cultures and the rate of cellular 
growth and viability. 
Immunocytochemistry (IHC) 
Normal human lung tissue samples and TLA tissue sec- 
15 tions designated for histological and immunohistological 
staining were washed three times with gentle agitation in 
CMF-PBS for 5 minutes to remove foreign protein residues 
contributed by the media. The TLAs were then transferred to 
50 ml polystyrene tubes and covered with 10% buffered for- 
20 malin in PBS (#15740, ELECTRON MICROSCOPY SCIENCE (EMS) 
TM Hatfield, Pa.) overnight at 4° C. and washed three times in 
PBS. TLAs were centrifuged at low speed (1000xg) to con-
centrate the bead-cell assembly. Warm noble agar (1 ml) was 
added for additional stabilization. TLAs were embedded in 
25 paraffin-blocks by standard methods, and light sections cut at 
3-5 um on a MICRON® HM315 microtome (Walldorf, Ger-
many). All unstained sections were stored at 20° until stained 
with haematoxylin and eosin (H&E) or with a panel of dif-
ferential and developmental membrane receptor antibodies. 
30 The sections were deparaffinized by normal procedure (Goodwin, 1988), antigen retrieved by protease or citrate, and 
blocked with a normal rabbit or mouse sera —0.5% TwEENO 
20 blocking solution. The primary antibody (as identified in 
Table 4) diluted in the blocking solution was incubated on 
35 sections between 9 and 30 minutes as required, rinsed with 
distilled water, and incubated with anti-mouse, -goat, or -rab-
bit-antibodies conjugated with horseradish peroxidase. The 
second antibody (DAKo ENVISION SYSTEMTM) was applied 
using an automated immunohistochemical stainer (DAKO(k, 
40 Carpinteria, Calif.). Slides were examined under a ZEiss® 
AxioSKOPTM (Hamburg, Germany) microscope and images 
captured with a KODAK® DC290 Zoom (Rochester, N.Y., 
USA) digital camera. 
45 TABLE 4 
HUMAN IMMUNOHISTOCHEMISTRY ANTIBODIES 
Antibody Manufacture Dilution 
Rabbit anti- ZO-1 Zymed, #61-7300 1:3000 
50 	 Mouse anti-Human Villin Neomarkers, Ezrin p81/80K 1:40 
Cytovillin Ab-1, Clone 3C12 
Mouse anti-Human EN/1A Dako, #N1504, Clone E29 1:1500 
Mouse anti-Human Dako, #N1596, Clone JC70A 1:500 
Endothelial Cell Membrane 
PECAM-1 (CD 31) 
55 	 Mucin Stain Kit Ventana Medical Systems NA 
Mouse anti-Human Dako, #M0888, Clone predilute 
Cytokeratin 8 RCK 108 
Mouse anti-Human Laminin Dako, #M0638, Clone 4C7 1:1000 
Mouse anti-Swine Vimentin Dako, #M0725, Clone V9 1:2000 
Mouse anti-Human Dako, #N1589, Clone LP34, predilute 
60 	 Cytokeratin 18 34 beta E12 
Rabbit anti-Human Von Dako, #N1505 1:75 
Willebrand Factor 
Fibronectin Dako 1:500 
Tubulin ProMega Cat. No. 1:1000 
#946, clone 5G8 
65 	 Collagen IV Dako #N1536 clone CIV 22 predilute 
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Transmission Electron Microscopy (TEM) 
TLA TEM samples were washed three times with 0.1 M 
sodium cacodylate buffer pH 7.4 (#11652, ELECTRON MICROS-
COPY SCIENCE (EMS)TM, Hatfield, Pa.) then fixed in a solution 
of 2.5% gluteraldehyde-formaldehyde in 0.1 M sodium 
cacodylate buffer (#15949, ELECTRON MICROSCOPY SCIENCE 
(EMS)TM, Hatfield, Pa.), 0.3 M sucrose (SIGMA®, St. Louis, 
Mo.), 1% DMSO (SIGMA®, St. Louis, Mo.) pH 7.4 overnight 
at 4° C. The fixed tissue was washed three times in O.1M 
sodium cacodylate buffer, pH 7.4 buffer, post-fixed stained in 
0.1 M tannic acid (#21700, ELECTRON MICROSCOPY SCIENCE 
(EMS)TM, Hatfield, Pa.) in 0.1 M sodium cacodylate pH 7.4 
for 3 hours at room temperature. The tissue samples were 
washed three times in buffer, and then fixed again in 1.0 M 
osmium tetroxide (#19152, ELECTRON MICROSCOPY SCIENCE 
(EMS)TM, Hatfield, Pa.) in cacodylate buffer pH 7.4 for 1.5 
hours at room temperature. Samples were dehydrated in a 
series of graded ETON, and then embedded in EMBED-
8I 2TM resin (#14120, ELECTRON MICROSCOPY SCIENCE (EMS)TM 
Hatfield, Pa.). Samples were sectioned at yellow-silver (700 
A), mounted on Ni grids and examined under a JEOL-JEM 
I OI OTM transmission electron microscope (JEOLO, Peabody, 
Mass.) at 80 W. 
Scanning Electron Microscopy (SEM) 
Samples from the RWV cultures were taken for SEM at the 
same times as those taken for growth kinetics and immuno-
cytochemistry. After removal from the reactor vessels, 
samples were washed once with CMF-PBS. The samples 
were suspended in a buffer containing 3% glutaraldehyde and 
2% paraformaldehyde in 0.1 M cacodylate buffer at pH 7.4 
(Luna, 1968), then rinsed for 5 minutes with cacodylate 
buffer three times and post-fixed with 1% osmium tetroxide 
(ELECTRON MICROSCOPY SCIENCE (EMS) TM, Hatfield, Pa.) in 
cacodylate buffer for 1 hour. Samples were then rinsed three 
times for 5 minutes each with distilled water and then treated 
for 10 minutes with a MILLIPORE® (Bedford, Mass.) (0.2-µm)-
filtered, saturated solution of thiocarbohydrazide (ELECTRON 
MICROSCOPY SCIENCE (EMS)TM, Hatfield, Pa.), thenwashed five 
times for 5 minutes each with distilled water and fixed with 
I% buffered osmium tetroxide for 10 minutes. This last step 
was necessary to prevent the microcarriers from collapsing. 
Samples were then rinsed with distilled water three times and 
dehydrated with increasing concentrations of EtOH, followed 
by three changes in absolute methanol. After transfer to 1,1, 
1,3,3,3-hexamethyldisilazane (ELECTRON MICROSCOPY SCIENCE 
(EMS)TM, Hatfield, Pa.), samples were allowed to soak for 10 
minutes, drained, and air-dried overnight. Dried samples 
were sprinkled with a thin layer of silver paint on a specimen 
stub, dried, coated by vacuum evaporation with platinum-
palladium alloy, and then examined in the JEOL T330TM 
scanning electron microscope (JEOLO, Peabody, Mass.) at 
an accelerating voltage of 5 to 10 W. 
Viral Infection of TLAs 
TLAs were infected as described previously. Briefly, TLAs 
were inoculated with wtRSV A2 (Lewis et al, 1961) and 
wtPIV3 JS (Belshe et al, 1982) at a MOI of 0.1. After virus 
absorption at room temperature for one hour, monolayers and 
TLA cultures were washed 3 times with DPBS (INVITROOENO, 
Carlsbad, Calif.) and fed with media specified above. All air 
bubbles were removed from the RWV before rotation to 
eliminate shearing of the cells (Goodwin et al, 1988) and 
before placing in a humidified incubator with 5% CO z at 35° 
C. Approximately 65% of the culture media was replaced 
every 48 hours for both monolayer and TLA cultures. 
Samples were collected at days 0, 2, 4, 6, 8, and 10 for virus 
titration. For RSV titration, I mL samples of the TLA cultures 
were flash-frozen with IXSPG. The titer was determined by 
12 
immunostaining in HEp-2 cells at 32° C. as previously 
described (Randolph et al, 1994). Titers of PIV3 viruses were 
determined in LLC-MK2 cells with medium overlay contain-
ing 0.8% agar at 32° C. as previously described (Karron et al, 
5 1995), except that plaques were visualized by an immun-
ostain assay described previously (Randolph et al, 1994) 
using anti-human PIV3 FIN and F antibodies. 
Immunostaining Fixed RSV-Infected TLAs 
Uninfected and TLAs (10 6 cells) infected with wtRSV A2 
i0 
were fixed at different times post infection (pi) as described 
(Cheutin et al, 2003). Briefly, EM grade paraformaldehyde 
(#1570, ELECTRON MICROSCOPY SCIENCE (EMS) TM, Hatfield, 
Pa.) was added to a final concentration of 4% after the TLAs 
15 were washed three times in DPBS (#21-030-CV, CELLOROO). 
After one hour, the TLAs were washed 3 more times with 
DPBS. The TLAs were permeablized in TRITONTM X-100 
(#T9284, SIGMA®, St. Louis, Mo.) for 5 minutes on ice. To 
avoid nonspecific binding the samples were incubated with 
20 1% BSA for 5 minutes followed by cold water fish gelatin 
(Fluka #48717) in PBS at room temperature for 10 minutes. 
The TLAs were incubated with 0.02 M glycine (FLUKA Bio-
CxEMIcALO #1050586) for 3 minutes to reduce autofluores-
ence. A 1:1000 dilution of RSV F (1334H and 143-6C) and 
25 G (131-1G) monoclonal antibodies (Anderson et al, 1988) 
were incubated for one hour; then the TLAs were washed 5 
times with 1% BSA. Texas Red dye conjugatedAETINIPURETM 
Goat anti-mouse IgG H+L (JACKSON INIMUNoRE SEARCH LABoRA-
TORIESO #115-075-146) was diluted 1:100 and 500 µ.L was 
30 
added to each sample for 1 hour, then washed 4 times with 
DPBS. TLAs were observed with an OLYMPUS® IX70 fluo-
rescent microscope. 
35 	
Example 2 
Growth Kinetics of TLAs 
TLAs were produced by inoculating a RW V using GTSF-2 
40 media with mesenchymal and epithelial lung cells in the 
presence of microcarriers. In one embodiment an aliquot of 
lung cells is expanded using 2D tissue culture flasks, 
trypsinized to dislodge the cells from the conical tube, bring 
the cells to a known cell density in an RWV with GTSF-2 
45 media, and incubated under microgravity conditions allowing 
the formation of TLAs. The cultures were monitored at 
24-hour time points for glucose utilization and pH. FIG. 3 
reflects a typical metabolic profile for these cultures. These 
data clearly demonstrate rapid uptake of glucose by TLAs 
50 with a slight decrease in pH over the initial growth period. 
Together these factors indicate an increase in cellular metabo-
lism commensurate with an increase in the size of the aggre-
gates. 
In one example, hBTC and BEAS-2B cells were initiated 
55 
as monolayers in human fibronectin coated flasks and propa- 
gated in GTSF-2 media supplemented with 10% fetal bovine 
serum (FBS). The cells were passaged as required by enzy- 
matic dissociation with a solution of 0.1% trypsin and 0.1% 
60 EDTA for 15 minutes at 37° C. The primary inoculum for 
each 55-m1 RW V with 5 mg/ml of CYTODEx-3TM microcarriers 
was 2x105 hBTC cells/ml. Cultures were allowed to grow for 
approximately 4 days as previously described. BEAS-213 epi- 
thelial cells were added at 2x10 5 cells/ml on day 4. As meta- 
65 bolic requirements increased, fresh medium was supple- 
mented with an additional 100 mg/dl of glucose. Experiments 
were cultured for up to 40 days total. Viable cocultures grown 
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in the RWV were harvested over periods up to 21 days and 
prepared for various activity assays. 
Example 3 
TLAs Express Markers of In Vivo Respiratory 
Epithelium (IHC) 
To compare the cellular composition and differentiation 
state of TLAs to normal human respiratory epithelium, fixed 10 
TLAs and normal human lung sections were immunostained 
for epithelial specific cell markers (FIG. 4, Table 4). The 
cytokeratins (Ke,1988; Sutherland, 1988) (FIG. 4G, FIG. 4H, 
FIG. 40, FIG. 4P) and Factor VIII (FIG. 4I, FIG. 47) antibod- 
ies detect epithelial, mesenchymal, and endothelial cells, 15 
respectively (Tsao, et al, 1992, Moyer, 1990, Woodcock-
Mitchell, et al, 1982, Vogel, et al, 1984, Shima, et al 1988). 
Tubulin (FIG. 4E, FIG. 4F), is a cytoskeletal protein found in 
epithelial cells. Endothelial markers, PECAM-1 (FIG. 4A, 
FIG. 413) and Factor VIII (FIG. 4I, FIG. 4J), are present in 20 
subsets of precursor endothelial cells, particularly dividing 
cells. Basement membrane and extracellular matrix compo-
nents (e.g., collagen IV, FIG. 4Y, FIG. 4Z) were also assayed 
to determine their expression in the TLAs. Expression of 
endothelial specific and basement membrane components 25 
(FIG. 47, FIG. 4Z) were frequently seen at cell-bead-aggre-
gate interfaces. Other markers were also selected to highlight 
epithelial characteristics including microvilli (Villin; FIG. 
4M, FIG. 4N) tight junctions (ZO-1; FIG. 4Q, FIG. 4R), and 
polarization (EMA; FIG. 4C, FIG. 4D). Expression of 30 
ICAM-1 (FIG. 4S, FIG. 4T) and cytokeratin 18 (FIG. 40, 
FIG. 4P) reflect a differentiated state. Positive staining for 
mucin (FIG. 4K, FIG. 4L) indicates production of mucus in 
the tissue. Of particular interest, FIG. 4T, FIG. 4N, and FIG. 
4F illustrate homogenous staining for cytoskeletal markers, 35 
ICAM-1, villin, and tubulin at the surfaces of most areas of 
the cell/microcarrier TLAs. Each of the cell specific cellular 
stains applied to TLAs compared favorably with the 3D 
human tissue controls shown in Table 5, thus confirming that 
fidelity to in situ respiratory epithelia is achieved. 	 40 
TABLE 5 
NATIVE CELLULAR DIFFERENTIATION 
45 
Tissue 	 3D/Nor Hu Lung 
Characterization Stains 	 Tissue 	 3D/TLA/BEAS-2B/ 
ICAM-1 	 4+ 	 3+ 
Villin 	 2+ 	 3+ 
Tubulin 	 3+ 	 4+ 
Cytokeratin 8 	 4+ 	 3+ 	 50 
Cytokeratin 18 	 3+ 	 4+ 
PECAM-1 	 3+ 	 4+ 
ZO-1 	 2+ 	 3+ 
EMA 	 4+ 	 2+ 
Hu Mucin 	 4+ 	 4+ 
VWR/FactorVIII 	 4+ 	 3+ 	 55 
Collagen IV 	 4+ 	 4+ 
Slides were scored on a relative scale: 0 (no staining), 1+ (weak staining), 2+weakstaining 
for 25-50% of the cells, 3+ indicates moderate staining for 50-75% of the cells, and 4+ 
indicates staining of 99% of the cells. 
60 
Example 4 
TLAs Display Structural Characteristics of the 
Human Respiratory Epithelia 
65 
TEMs of uninfected TLAs (FIG. 5A-FIG. 5F) illustrate 
many features ofnormal tissue and demonstrate recapitulated 
14 
respiratory epithelium polarized with apical and basolateral 
sides reinforcing the IHC data. TEMs of thin sections of 
TLAs illustrate human respiratory epithelial characteristics 
including a multi-layered structure punctuated by extracellu-
lar matrix and pseudo-stratified mesenchymal and epithelial 
layers (FIG. 5A, FIG. 513). Multiple cell types are shown in 
(FIG. 5C, FIG. 5D); the nuclei of mesenchymal cells (on 
bead) are elongated and the nuclei of epithelial cells are 
rounded. FIG. 5E and FIG. 5F the center of both micrographs 
demonstrates conformational data showing tight junctions 
(T7) also represented by ZO-1 IHC staining. Microvilli, 
stained by villin and tubulin on IHC can be seen in FIG. 5F. In 
light of the functional studies above and these structural stud-
ies, the recapitulated 3D models emulate complex cellular 
relationships of in situ airway epithelium. 
Example 5 
TLAs Infection with Respiratory Viruses 
TLAs produced as described in Example 1, were infected 
with wtRSV A2 and wtPIV3 7S. In one embodiment, TLAs 
were inoculated with wtRSV A2 and wtPIV3 7S at a MOI of 
0.1. After virus absorption at room temperature for one hour, 
monolayers and TLA cultures were washed 3 times with 
DPBS and fed with media specified above. All air bubbles 
were removed from before placing in a humidified incubator. 
Media was replaced every 48 hours. Samples were collected 
at days 0, 2, 4, 6, 8, and 10 for virus titration. Similar 2D 
cultures were treated similarly as a control. 
Scanning Electron Microscopy (SEM) 
TLA samples were collected at intervals across the initial 
growth experiment (FIG. 6A, FIG. 6B uninfected) and post 
infection (pi) (FIG. 6C-FIG. 6F) and were prepared for scan-
ning electron microscopy as stated previously. Photomicro-
graphs taken of day 2-12 cocultures pi showed viral presence 
and cellular damage (FIG. 6C, FIG. 6D). FIG. 6E demon-
strates cell surface damage analogous to pockmarks at 8 days 
pi. In FIG. 6F, 12 days pi, an insert of budding virus is visible. 
Samples harvested at approximately 12 days of culture con-
tained small microcarrier bead packs that were totally 
engulfed in proliferating TLA epithelium despite viral infec-
tion (FIG. 6E, FIG. 6F). Additionally, at 21 days large prolif-
erating masses of TLAs (>3.5 mm) were evident, growing on 
the microcarrier bead packs pi. 
Transmission Electron Microscopy (TEM) 
TLAs were infected as previously stated. (FIG. 7A-FIG. 
7F) illustrates the time course of infection into the TLAs from 
0-12 days respectively. TEMs of all TLAs subjected to virus 
demonstrated infection beginning as early as 1 hour pi, FIG. 
713, and continuing through day 12 pi FIG. 7F. Viral nucleo-
capsids (VNC) were found to locate through out the cells and 
in the perinuclear regions (FIG. 713, FIG. 7E and FIG. 7F) and 
were overtly apparent in both RSV and PIV3 infected TLAs. 
Mature virus particles are formed when VNCs bud from the 
cell membrane containing the viral glycoproteins thus bud-
ding virus was present beginning at day 2 (FIG. 7C) and day 
4 (FIG. 7D) and continuing throughout the course of the 
infection. 
Viral Protein and Titer Data 
Photographs of fluorescently stained TLAs, specific for 
two RSV glycoproteins (F and G) that increased in concen-
tration (Days 2-10), are shown in (FIG. 8A-FIG. 8D). FIG. 9 
illustrates viral growth kinetics up to day 21 pi withwtRSVA2 
and wtPIV3 7S. As illustrated, wtPIV3 7S replicates more 
efficiently than wtRSVA2 in TLAs. Peak replication is on day 
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7 for wtPIV3 7S (approximately 7 log 10 particle forming 
units (pfu) per mL) and on day 10 for wtRSVA2 (approxi-
mately 6 log 10 pfu/mL). 
TLAs provide an exemplary model of human lung tissue, 
forming 3D tissue models of in situ respiratory epithelial 
cells. The infection of these cells with RSV and PIV is one 
indication of complex respiratory epithelia formation. The 
budding virus particles, progression of infection and long 
term growth of the infected TLAs provide a background for 
additional assays and monitoring of disease progression in 
vitro. 
Example 6 
Screening for Antiviral Compounds (Prophetic) 
TLAs produced as described in the above examples and 
infected with a virus as previously described, provide an in 
vitro model for lung infection. To identify antiviral com-
pounds TLAs infected with a virus provide a method of 
screening libraries of compounds for antiviral activity and 
lung tissue toxicity. TLAs contacted with a test compound are 
compared to TLAs contacted with a known compound, TLAs 
infected with a virus only, and uninfected TLAs only. Anti-
viral activity can be measured phenotypically by noting viral 
bud formation or quantitatively by counting the number and 
size of virus buds. Other measures of cellular or viral activity 
are known and can be easily measured. 
In one embodiment, TLAs are produced and infected with 
a viral strain. Infected and non-infected TLAs are placed in a 
series of cultures (from arrayed slides or microplates to larger 
cultures or RW V) and growth is compared in the presence or 
absence of antiviral compounds. Various measures of viral 
titer and TLA viability can then be assessed in vitro including 
the methods described in the previous examples. Antiviral 
compounds such as zinc, TAMIFLU TM (oseltamivirphosphate), 
WIN 52084 (anti-rhinoviral) or other antivirals can be com-
pared to test compounds in a laboratory setting using the TLA 
model system. 
Example 7 
Screening for Cystic Fibrosis Treatments (Prophetic) 
TLAs produced as described in Example 1, can be created 
using cystic fibrosis (CF) variants of HBEs including CFS-
MEo, CFBE410-, and I133-1. By comparing the surfactants, 
proteases, and mucous produced with CF epithelium to nor-
mal HBEs, differences in the TLAs can be measured qualita-
tively and quantitatively. To identify novel CF treatments, 
CF-TLAs can be used to screen libraries of compounds for 
changes in mucous, increase in surfactant, and other proper-
ties of normal or CF epithelia. Similar TLAs with known CF 
treatments and without a test compound provide positive and 
negative controls. CF-TLAs can also be assayed along with 
WT TLAs to provide additional controls. 
In one embodiment, TLAs are produced with hBTC mes-
enchymal cells and either CFSMEo (CF) or BEAS-213 (wt) 
epithelial cells as previously described. Cultures of CF TLAs 
and wt TLAs are isolated and split into 2 sets of cultures. One 
pair of CF and wt cells are exposed to a test compound 
(experimental), the other pair are similarly treated in the 
absence of test compound (control). Cell morphology, 
mucous, and surfactant measurements are made. Candidate 
compounds that reduce CF related traits in TLAs can be 
identified and used to develop CF treatments. 
16 
Example 8 
Assessing Allergens and Lung Toxicity (Prophetic) 
5 	 TLAs provide an in vitro model of lung tissue. They pro- 
duce inflammatory response modifiers, endocrine, autocrine, 
paracrine, and cytokine factors that are indicative of allergic 
response. Similar TLAs exposed to known allergens, irritants, 
and/or unknown test compounds provide a rapid in vitro assay 
l0 
of allergens and/or lung tissue toxicity. 
In one embodiment, TLAs are produced with hBTC mes-
enchymal cells and BEAS-213 epithelial cells as previously 
described. Cultures TLAs are isolated and spread onto a 
15 matrix of known (control) and test compounds (experimen-
tal). Cell markers, including apoptosis markers and inflam-
matory response modifiers, are used qualitatively or quanti-
tatively measure the effect of known and test compounds over 
time. Compounds which reduce or delay the onset of inflam- 
20 matory response are identified as anti-allergenic compounds. 
Compounds which induce apoptotic response are identified 
as cytotoxic. 
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What is claimed is: 
1. A method of assaying a test compound for a therapeutic, 
allergenic, or cytotoxic activity with three-dimensional 
human broncho-epithelial tissue-like assemblies comprising: 
inoculating a rotating wall vessel comprising microcarriers 
in culture media with mesenchymal bronchial-tracheal 
cells, wherein said microcarriers and said culture media 
are selected to have a difference in density from 90% to 
95% or 105% to 110%, wherein said difference in den- 
20 
sity is defined as 100 times the fraction of the microcar- 
rier's density over the culture media's density; 
growing bronchial-tracheal cells for 24 to 240 hours; 
inoculating said rotating wall vessel with bronchial epithe- 
5 	 lium cells to generate a coculture; 
growing said coculture for 24 to 960 hours to produce 
tissue-like assemblies wherein said tissue-like assem-
blies express markers of in vivo respiratory epithelia and 
display structural characteristics of in vivo respiratory 
l0 	
epithelia; 
dividing said coculture into two or more separate cocul-
tures comprising at least one experimental tissue like 
assembly and one or more control tissue-like assem- 
15 	 blies; 
incubating said at least one experimental tissue-like assem-
bly and said one or more control tissue-like assemblies 
under similar conditions; 
infecting said at least one experimental tissue-like assem-
20 bly with a virus; 
proliferating said virus for a predetermined timeframe up 
to about 504 hours; 
contacting at least one experimental tissue-like assembly 
from a first coculture to said test compound, wherein 
25 	 said test compound is an antiviral compound; 
measuring a phenotypic, genetic or quantitative trait for 
each tissue-like assemblies; and 
determining said therapeutic, allergenic, or cytotoxic activ-
ity of said antiviral compound by comparing said phe- 
30 notypic or quantitative trait in said at least one experi-
mental tissue-like assembly to said one or more control 
tissue-like assemblies. 
2. The method of claim 1, wherein said virus is selected 
from the group consisting of respiratory syncytial virus 
35 (RSV), human respiratory syncytial virus A-2, human respi-
ratory syncytial virus B, human respiratory syncytial virus 
9320, human respiratory syncytial virus Wash/18537/'62, 
human respiratory syncytial virus Long (VR-26), parainflu-
enza virus (PIV), parainfluenza virus 1, parainfluenza virus 2, 
40 parainfluenza Greer, Parainfluenza 4a, parainfluenza 4b, 
parainfluenza 5 DA, human rhinoviruses (HRV), coxsack-
ieviruses, echoviruses, severe acute respiratory syndrome 
(SARS), adenovirus, influenza A and B, hantavirus, cytome-
galovirus (CMV), paramyxovirus species (measles), vari- 
45 cella-zoster virus, Epstein-Barr virus, herpes simplex virus, 
and human immunodeficiency virus (HIV). 
3. The method of claim 1, wherein said bronchial epithe-
lium cells are selected from the group consisting of cystic 
fibrosis (CF) epithelium, CFSMEo-, and CFBE410-; and said 
50 test compound reduces symptoms of CF. 
4. The method of claim 1, wherein said first coculture 
tissue-like assemblies are assessed for endocrine, autocrine, 
paracrine, and cytokine factors that are indicative of allergic 
response. 
55 	 5. The method of claim 1, wherein said first coculture 
tissue-like assemblies are assessed for endocrine, autocrine, 
paracrine, and cytokine factors. 
6. The method of claim 1, wherein said rotating wall vessel 
is comprised of a culture chamber rotatable about an approxi- 
60 mately horizontal longitudinal axis, means to controllably 
rotate said culture chamber, means to introduce an oxygen-
containing fluid throughout said culture chamber, and means 
to remove metabolic waste products therefrom. 
7. The method of claim 6, wherein said means to control- 
65 lably rotate said culture chambers is comprised of controlling 
the rotation of said culture chamber such that the fluid 
medium has the following properties; 
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collocation of said culture media with said bronchial-tra-
cheal cells, 
essentially no relative motion of said culture media with 
respect to the boundaries of said chamber, 
freedom for three-dimensional spatial orientation of said 
tissue-like assemblies formed by said growing of said 
coculture. 
8. The method of claim 1, wherein said predetermined 
timeframe is greater than 96 hours. 
9. The method of claim 1, wherein the step of proliferating 
is comprised of: 
allowing said virus to absorb into said tissue-like assem-
blies for about one hour at room temperature, wherein 
room temperature is a temperature from 20° C. to 25' C.; 
washing said at least one experimental tissue-like assem-
bly infected with said virus 3 times with Dulbecco's 
phosphate buffered saline after said step of allowing; 
and 
feeding said at least one experimental tissue-like assembly 
with a culture media after said step of washing. 
10. The method of claim 9, wherein the step of proliferating 
is further comprised of: 
removing substantially all air bubbles from said rotating 
wall vessel after said step of feeding; 
placing said rotating wall vessel in a humidifier after said 
step of removing. 
11. The method of claim 10, wherein said humidifier pro-
duces and maintains an environment comprised of about 5% 
carbon dioxide at a temperature of about 35 degrees Celsius. 
12. The method of claim 10, wherein the step of prolifer-
ating is further comprised of: 
replacing about 65 percent of said culture media about 
every about 48 hours until the end of said timeframe. 
13. The method of claim 1, wherein said measuring step is 
comprised of immunohistochemistry and results thereof, 
wherein said markers comprise cytokeratin 8 and cytokeratin 
18, and wherein said results comprise staining of 99% of the 
cells of saidtissue-like assemblies for said cytokeratin 18, and 
from 50% to 75% of the cells of said tissue-like assemblies for 
said cytokeratin S. 
14. The method of claim 13, wherein said results comprise 
staining of 99% of the cells of said tissue-like assemblies for 
said cytokeratin 18. 
15. The method of claim 13, wherein said markers further 
comprise Factor VIII and wherein said results further com-
prise staining from 50% to 75% of the cells of said tissue-like 
assemblies for Factor VIII. 
22 
16. The method of claim 1, wherein said measuring step is 
comprised of immunohistochemistry and results thereof, 
wherein said markers comprise tubulin, and wherein said 
results comprise staining of 99% of the cells of said tissue- 
s like, assemblies for said tubulin. 
17. The method of claim 1, wherein said measuring step is 
comprised of immunohistochemistry and results thereof, 
wherein said markers comprise PECAM-1 and Factor VIII, 
and wherein said results comprise staining from 50% to 75% 
10 
of the cells of said tissue-like assemblies for said Factor VIII 
and staining of 99% of the cells of said tissue-like assemblies 
for said PECAM-1. 
18. A method of assaying a test compounds for a therapeu- 
tic, allergenic, or cytotoxic activity with three-dimensional 
15 human broncho-epithelial tissue-like assemblies comprising: 
inoculating a rotating wall vessel comprising microcarriers 
in culture media with mesenchymal bronchial-tracheal 
cells, wherein said microcarriers and said culture media 
are selected to a difference in density from 90% to 95% 
or from 105% to 110%, wherein said difference in den- 
sity is defined as 100 times the fraction of said micro- 
carrier's density over said culture media's density; 
growing bronchial-tracheal cells for 24 to 240 hours; 
inoculating said rotating wall vessel with bronchial epithe-
lium cells to generate a coculture; 
25 	 growing said coculture for 24 to 960 hours to produce 
tissue-like assemblies wherein said tissue-like assem- 
blies express markers of in vivo respiratory epithelia and 
display structural characteristics of in vivo respiratory 
30 	
epithelia; 
dividing said coculture into two or more separate cocul-
tures comprising at least one experimental tissue-like 
assembly from a first coculture and one or more control 
tissue-like assemblies from one or more cocultures; 
35 contacting said at least one experimental tissue-like assem-
bly to said test compound; 
incubating said at least one experimental tissue-like assem-
bly and said one or more control tissue-like assemblies 
under similar conditions; 
measuring a phenotypic, genetic or quantitative trait for 
4o 
each tissue-like assemblies, wherein said measuring 
stop is comprised of immunohistochemistry and results 
thereof; and 
determining said therapeutic, allergenic, or cytotoxic activ-
ity by comparing said phenotypic or quantitative trait in 
45 	
said at least one experimental tissue-like assembly to 
said one or more control tissue-like assemblies. 
